Kala Pharmaceutical announced that the Food and Drug Administration (FDA) has approved Eysuvis for the short-term treatment of dry eye syndrome. Unlike other prescription therapies, Eysuvis is a corticosteroid, Corticosterioids are commonly used as an off-label treatment for dry eye.
The two main prescription therapies currently in use are Allergan's Restasis (cyclosporine emulsion) and Novartis Xiidra (liftegrast solution). Both of these take longer to have an effect while Eysuvis will have a quicker onset of action.
Restasis has been available since 2003 and Xiidra has been available since 2016 but both have been linked to patient dissatisfaction issues and poor patient tolerability along with their slow onset of action.
Andrea Schumann is Customer Service Manager for Vitamin Science and is a regular contributor to the Shop VisiVite Blog. Andrea has a Bachelor of Science degree in Business Administration from Central Methodist University.